Kamada Ltd. (NASDAQ:KMDA) – Jefferies Group reduced their FY2018 earnings per share estimates for Kamada in a research note issued on Friday. Jefferies Group analyst R. Denhoy now expects that the biotechnology company will post earnings of $0.19 per share for the year, down from their prior estimate of $0.20. Jefferies Group currently has a “Buy” rating and a $7.00 target price on the stock. Jefferies Group also issued estimates for Kamada’s FY2019 earnings at $0.39 EPS and FY2020 earnings at $0.64 EPS.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.94%. The firm had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $33.30 million. During the same quarter last year, the company earned ($0.04) EPS. The firm’s revenue for the quarter was up 70.7% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/research-analysts-issue-forecasts-for-kamada-ltd-s-fy2018-earnings-kmda/1532002.html.

A number of other research firms have also recently commented on KMDA. Zacks Investment Research upgraded Kamada from a “sell” rating to a “hold” rating in a report on Tuesday, August 15th. TheStreet cut Kamada from a “c-” rating to a “d+” rating in a report on Tuesday, August 1st.

Kamada (KMDA) traded up 1.16% during midday trading on Monday, reaching $4.35. 89,702 shares of the company were exchanged. The company’s market capitalization is $162.69 million. Kamada has a 52-week low of $3.75 and a 52-week high of $8.61. The company has a 50 day moving average of $4.95 and a 200-day moving average of $6.49.

A number of institutional investors have recently bought and sold shares of KMDA. Vanguard Group Inc. boosted its position in Kamada by 6.5% in the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after buying an additional 28,382 shares during the last quarter. Nexthera Capital LP bought a new stake in shares of Kamada during the second quarter valued at about $1,805,000. Renaissance Technologies LLC increased its stake in shares of Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock valued at $1,801,000 after buying an additional 37,800 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Kamada during the first quarter valued at about $575,000. Finally, Norges Bank bought a new stake in shares of Kamada during the fourth quarter valued at about $377,000. Institutional investors and hedge funds own 7.15% of the company’s stock.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.